Advertisement

Update 1987 pp 287-292 | Cite as

Inotropic Therapy in Acute Circulatory Failure

  • E. Installé
Part of the Update in Intensive Care and Emergency Medicine book series (UICM, volume 3)

Abstract

Various definitions of “acute circulatory failure” (ACF) can be given according to the criteria considered as most meaningful (cardiac output, systemic pressures or others). In this article, we will define ACF in terms of inappropriate peripheral (tissular or even better, cellular) oxygen supply. This definition has the advantage to clearly specify that the therapy has to aim to improvement of oxygen tissular delivery, i.e. to optimization of arterial O2 content and O2 transport. Optimization of arterial O2 content is not the subject of this discussion, but O2 transport is the basis of our topic. O2 transport does not only depend on cardiac output: considerations about microcirculation and rheology would be here of primary importance but, once again, fall outside our topic. In treating ACF we have to take into account the quality of tissular perfusion.

Keywords

Pulmonary Vascular Resistance Inotropic Agent Adrenergic Agonist Severe Congestive Heart Failure Ventricular Filling Pressure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Colucci WS, Wright RF, Braunwald E (1986) New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments (First of two parts). N Engl J Med 314:290–299PubMedCrossRefGoogle Scholar
  2. 2.
    Colucci WS, Wright RF, Braunwald E (1986) New postive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments (Second of two parts). N Engl J Med 314:349–358PubMedCrossRefGoogle Scholar
  3. 3.
    Mueller HS (1985) Inotropic agents in the treatment of cardiogenic shock. World J Surg 9:3–10PubMedCrossRefGoogle Scholar
  4. 4.
    Handler CE (1985) Cardiogenic shock. Postgraduate Med J 61:705–712CrossRefGoogle Scholar
  5. 5.
    Baumann G (1986) Acute effects of dopexamine hydrochloride, in comparison to dobutamine and nitroprussiate in patients with chronic cardiac failure. X World congress of cardiology, Washington DC, Abstract book, 1077Google Scholar
  6. 6.
    Foulds RA, Magrini F, Zanchetti A (1986) The renovascular effects of dopexamine hydrochloride, a dopaminergic and β2 adrenergic agonist. X World congress of cardiology, Washington DC, Abstract book, 1151Google Scholar
  7. 7.
    Colardyn F (1986) Acute and long-term haemodynamic effects of dopexamine hydrochloride in patients with chronic cardiac failure. X World congress of cardiology, Washington DC, Abstract book, 1980Google Scholar
  8. 8.
    Mancini D, LeJemtel T, Sonnenblick E (1985) Intravenous use of amrinone for the treatment of the failing heart. Am J Cardiol 56:8B–15BPubMedCrossRefGoogle Scholar
  9. 9.
    Sonnenblick EH, Grose R, Strain J, Zelcer AA, LeJemtel T (1986) Effects of milrinone on left ventricular performance and myocardial contractility in patients with severe heart failure. Circulation 73:III-162–167Google Scholar
  10. 10.
    Uretsky BF, Valdes AM, Reddy PS (1986) Positive inotropic therapy for short-term support and long-term management of patients with congestive heart failure : hemodynamic effects and clinical efficacy of MDL 17,043. Circulation 73:III-219–229Google Scholar
  11. 11.
    Petein M, Levine TB, Cohn JN (1984) Hemodynamic effects of a new inotropic agent, MDL 19,205, in patients with chronic heart failure. J Am Coll Cardiol 2:364–370CrossRefGoogle Scholar
  12. 12.
    Renard M, Liebens I, Walter M, Bernard R (1986) Acute and long-term response to oral pimobendan (UD-CG115) in patients with congestive heart failure. X World congress of cardiology, Washington DC, Abstract book, 1177Google Scholar
  13. 13.
    Jafri SM, Burlew BS, Goldberg AD, Rogers A, Goldstein S (1986) Hemodynamic effects of a new type III phosphodiesterase inhibitor (CI-914) for congestive heart failure. Am J Cardiol 57:254–259PubMedCrossRefGoogle Scholar
  14. 14.
    Daly PA, Chatterjee K, Viquerat CE, Parmley WW, Curran D, Scheinbaum M, Anderson S (1985) RO13-6438, a new inotrope-vasodilator: systemic and coronary hemodynamic effects in congestive heart failure. Am J Cardiol 55:1539–1544PubMedCrossRefGoogle Scholar
  15. 15.
    Salzmann R, Scholtysik G, Clark B, Berthold D (1986) Cardiovascular actions of DPI 201-106, a novel cardiotonic agent. J Cardiovasc Pharmacol 8:1035–1043PubMedCrossRefGoogle Scholar
  16. 16.
    Domb M, Van der Linden P, Azimi G, Motte S, de Boelpaepe C, Vincent JL (1986) Treatment of septic shock with amrinone: an experimental study. Crit Care Med 14:347CrossRefGoogle Scholar
  17. 17.
    Vincent JL, Van Reeth O, Van Bogaert E, Berré J, Kahn R (1986) Use of the new inotropic agent ARL-115 BS to treat severe myocardial depression in septic shock. Crit Care Med 14:661–662CrossRefGoogle Scholar
  18. 18.
    Massari FM, Foresti A, Valentini R, Bertoni T, De Martini M, Lotto A (1986) Clinical and hemodynamic evaluation of amrinone in acute myocardial infarction complicated by cardiogenic shock. X World congress of cardiology, Washington DC, Abstract book, 2524Google Scholar
  19. 19.
    Taylor SH, Verma SP, Hussain M, Reynolds G, Jackson NC, Hafizullah M, Richmond A, Silke B (1985) Intravenous amrinone in left ventricular failure complicated by acute myocardial infarction. Am J Cardiol 56:29B–32BPubMedCrossRefGoogle Scholar
  20. 20.
    Goenen M. Pedemonte O, Baele P, Col J (1985) Amrinone in the management of low cardiac output after open heart surgery. Am J Cardiol 56:33B–38BPubMedCrossRefGoogle Scholar
  21. 21.
    Installé E, Gonzalez M, Jacquemart JL, Guillaume JE, Anton E, Tremouroux J (1986) Efficacy of enoximone (MDL 17043) in refractory post-cardiac surgery low output syndrome. Acta Pharmacol Toxicol 59, Suppl V:182Google Scholar
  22. 22.
    Installé E, Gonzalez M, Jacquemart JL, Collard P, Roulette F, Pourbaix S, Tremouroux J. Comparative effects on hemodynamics of enoximone (MDL 17,043), dobutamine, and ni-troprusside in patients with severe congestive heart failure. Am J Cardiol (in press)Google Scholar
  23. 23.
    Monrad ES, Baim DS, Smith HS, Lanoue AS (1986) Milrinone, dobutamine, and nitroprus-side: comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure. Circulation 73:III-168–174CrossRefGoogle Scholar
  24. 24.
    Likoff MJ, Ulrich S, Hakki A, Iskandrian AS (1986) Comparison of acute hemodynamic response to dobutamine and intravenous MDL 17,043 (enoximone) in severe congestive heart failure secondary to ischemic cardiomyopathy or idiopathic dilated cardiomyopathy. Am J Cardiol 57:1328–1334PubMedCrossRefGoogle Scholar
  25. 25.
    Uretsky BF, Generalovich T, Verbalis JG, Valdes AM, Reddy PS (1986) Comparative hemodynamic and hormonal response of enoximone and dobutamine in severe congestive heart failure. Am J Cardiol 58:110–116PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • E. Installé

There are no affiliations available

Personalised recommendations